lifestyle.thedishh.com

Author: Innovent Biologics,Inc

Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China’s National Reimbursement Drug List

December 7, 2025
Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies

December 6, 2025
China’s First Domestic IL-23p19 Monoclonal Antibody: Innovent’s PECONDLE® (Picankibart Injection) Received NMPA Approval

November 28, 2025
Mazdutide 9mg Supplementary Application Accepted for Review by China’s NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population

November 25, 2025
Innovent Biologics Enters Hang Seng Index and Two Other Major Indices; Global Capital Markets Recognize Leading Innovator’s Value

November 24, 2025
Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints

November 22, 2025
Multiple Research Results from Innovent’s General Biomedicine Pipeline Showcased at 2025 ACR Annual Meeting

November 7, 2025
Innovent’s Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3

October 26, 2025
Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent’s Next Gen IO Backbone Therapy and ADC Molecules to the Global Market

October 22, 2025